BCAX Stock Analysis: Buy, Sell, or Hold?
BCAX - Bicara Therapeutics Inc. Common Stock
$19.04
0.67 (3.65%)
▲
5d:
+3.53%
30d:
+13.47%
90d:
+13.33%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Smart Money Distribution
BCAX is up 10.0% this week, but smart money is buying puts. Top strike: $20 2026-04-17 with 366 OI. Put ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When BCAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BCAX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BCAX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BCAX is currently trading at $19.04, which is considered slightly high relative to its 30-day fair value range of $17.17 to $19.44.
Technical Outlook: Technically, BCAX is in a uptrend. The price is approaching resistance at $19.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (99th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $29.75 (+56.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BCAX is in a uptrend. The price is approaching resistance at $19.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (99th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $29.75 (+56.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$17.17 -
$19.44
Company Quality Score
58/100
(HOLD)
Options IV Signal
99th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Options expensive (IV 99th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 56.3% below Wall St target ($29.75)
Fair Price Analysis
30-Day Fair Range
$17.17 -
$19.44
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.82
(20.0%)
Support & Resistance Levels
Support Level
$17.63
Resistance Level
$19.50
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.50
Wall Street Target
$29.75
(+56.3%)
Share & Embed Analysis
Last updated: March 31, 2026 12:21 AM ET
Data refreshes hourly during market hours. Next update: 1:21 AM
Data refreshes hourly during market hours. Next update: 1:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Ryan Cohlhepp
SELL
12500 shares
2026-03-16
Claire Mazumdar
SELL
36766 shares
2026-03-09
Claire Mazumdar
SELL
3817 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
